Reference number(s)
6701-H

Specialty Quantity Limit
Vyalev

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Vyalev	foscarbidopa/foslevodopa injection for subcutaneous use

Program Description

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

Covered Quantities

Medication	Standard Limit
Vyalev (foscarbidopa/foslevodopa injection for subcutaneous use) 12 mg/240 mg per mL (10 mL single-dose vial)	56 vials per 28 days

FDA-recommended Dosing

The continuous infusion rate is based on total levodopa dosage (TLD). All dosages of the levodopa-containing medications being replaced should be converted to the equivalent dosage of immediate-release levodopa to obtain the TLD. Do not include rescue or as needed levodopa or any other anti-Parkinsonian medication or therapy, including medications taken outside of awake time (e.g., night-time dosing) in the TLD. Multiply the TLD by 1.3 to obtain the total daily dosage of the foslevodopa component.

If therapy is being initiated in an “Off” state or the patient has not been receiving their base continuous infusion for more than 3 hours, a loading dose can be administered immediately prior to starting or re-starting the base continuous hourly infusion.

Extra dose(s) may be administered under provider discretion.

The maximum recommended daily dosage is 3,525 mg of the foslevodopa component (equivalent to approximately 2,500 mg levodopa).

References

1. Vyalev [package insert]. North Chicago, IL: AbbVie Inc.; October 2024.